Sozinibercept (OPT-302)
Wet Age-Related Macular Degeneration (Wet AMD)
Key Facts
About Opthea
Opthea is a publicly traded biotech dedicated to addressing significant unmet needs in retinal vascular diseases. Its core innovation is sozinibercept (OPT-302), a soluble VEGF-C and VEGF-D inhibitor that, when combined with standard-of-care anti-VEGF-A drugs, aims to provide superior efficacy by blocking a broader spectrum of angiogenic pathways. The company's strategic direction is centered on completing its Phase 3 program for wet AMD and DME, with the goal of establishing a new standard of care. Key achievements include positive Phase 2b data and the initiation of two global Phase 3 trials (COAST and ShORe).
View full company profileAbout Opthea
Opthea is a publicly traded biotech dedicated to addressing significant unmet needs in retinal vascular diseases. Its core innovation is sozinibercept (OPT-302), a soluble VEGF-C and VEGF-D inhibitor that, when combined with standard-of-care anti-VEGF-A drugs, aims to provide superior efficacy by blocking a broader spectrum of angiogenic pathways. The company's strategic direction is centered on completing its Phase 3 program for wet AMD and DME, with the goal of establishing a new standard of care. Key achievements include positive Phase 2b data and the initiation of two global Phase 3 trials (COAST and ShORe).
View full company profileAbout Opthea
Opthea is a publicly traded biotech dedicated to addressing significant unmet needs in retinal vascular diseases. Its core innovation is sozinibercept (OPT-302), a soluble VEGF-C and VEGF-D inhibitor that, when combined with standard-of-care anti-VEGF-A drugs, aims to provide superior efficacy by blocking a broader spectrum of angiogenic pathways. The company's strategic direction is centered on completing its Phase 3 program for wet AMD and DME, with the goal of establishing a new standard of care. Key achievements include positive Phase 2b data and the initiation of two global Phase 3 trials (COAST and ShORe).
View full company profileTherapeutic Areas
Other Wet Age-Related Macular Degeneration (Wet AMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| OTX-TKI (axitinib implant) | Ocular Therapeutix | Phase 3 |
| DURAVYU™ (EYP-1901) | EyePoint Pharmaceuticals | Phase 3 |
| 4D-150 | 4D Molecular Therapeutics | Phase 3 |
| ONS-5010 / LYTENAVA™ (bevacizumab-vikg) | Outlook Therapeutics | Approved |